BlueTree Venture Fund

BlueTree Venture Fund is a venture capital firm focused on early-stage investments in medical technologies, software, and high-tech instrumentation companies within a 250-mile radius. The firm aims to align its investments with the regional technology landscape and leverage its expertise to support portfolio companies. BlueTree Venture actively seeks businesses that showcase innovative technologies, possess strong management teams, and employ capital-efficient business strategies. The firm emphasizes opportunities for exit through strategic acquisitions, enabling it to provide hands-on mentorship and guidance to the companies it invests in.

Roger Byford

Managing Partner

David Motley

Managing Partner

Catherine Mott

Leading Founder / Managing Partner

Jon Pastor

Venture Partner

7 past transactions

Foundersuite

Series A in 2024
Foundersuite, Inc. is a software company that specializes in providing startup management tools for entrepreneurs. Founded in 2012 and based in San Francisco, it offers a suite of applications designed to streamline various aspects of startup operations, including corporate housekeeping, finance, hiring, and planning. Key features of its platform include an Investor CRM for managing investor relationships and fundraising processes, an Investor Search tool, and a Progress Tracker to monitor company advancements. Additionally, the company provides resources such as Idea Validation modules, Startup Docs, and a Company Tracker for competitive analysis. Foundersuite also develops an API that allows users to create and integrate additional tools and plugins. Its comprehensive approach aims to help entrepreneurs focus on product development, sales, and team management while effectively handling their administrative tasks.

Cypris

Venture Round in 2024
Cypris is a technology company founded in 2019 and headquartered in New York City. It specializes in providing a platform that centralizes innovation data, making it accessible and actionable for research and development teams. By leveraging artificial intelligence, Cypris offers insights drawn from a wide array of sources, including global patents, research papers, and market news. This comprehensive approach enables clients to inform critical decisions related to acquisitions, new patent filings, startup investments, and technology transfer agreements. The platform's user-friendly and collaborative design aims to enhance the efficiency of R&D strategies and accelerate innovation processes.

Cypris

Series A in 2023
Cypris is a technology company founded in 2019 and headquartered in New York City. It specializes in providing a platform that centralizes innovation data, making it accessible and actionable for research and development teams. By leveraging artificial intelligence, Cypris offers insights drawn from a wide array of sources, including global patents, research papers, and market news. This comprehensive approach enables clients to inform critical decisions related to acquisitions, new patent filings, startup investments, and technology transfer agreements. The platform's user-friendly and collaborative design aims to enhance the efficiency of R&D strategies and accelerate innovation processes.

Instant Teams

Series A in 2022
Instant Teams, Inc. offers a remote workforce management platform that connects businesses with high-quality talent, primarily drawing from military spouses and underserved communities. The company's technology platform, Arti, assists hiring managers by defining talent needs and timelines, while matching them with pre-qualified, native English-speaking team members. In addition to recruitment, Instant Teams provides comprehensive management tools for payroll, compliance, time tracking, and reporting, supporting the entire employee lifecycle. Founded in 2016 and based in Rehoboth Beach, Delaware, Instant Teams aims to address the challenges of talent acquisition and retention in customer support and operational roles. Its client roster includes notable companies such as Walmart, Amazon, and CrowdStrike, demonstrating the effectiveness of its plug-and-play solution for scaling support operations.

Peptilogics

Series A in 2017
Peptilogics, Inc. is a biotechnology company based in West Mifflin, Pennsylvania, that focuses on developing novel peptide therapeutics to combat multidrug-resistant bacterial infections. Established in 2013, Peptilogics employs a unique computational platform that facilitates drug discovery by exploring new chemical design spaces and ensuring the biological viability and manufacturability of potential therapeutics. The company's lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that has received FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation, targeting prosthetic joint infections, which represent a significant unmet medical need. Peptilogics aims to provide effective solutions to address the challenges posed by resistant bacteria and biofilms, ultimately improving treatment outcomes for patients.

Iteros

Series A in 2017
Iteros is an energy software company specializing in the modeling, control, and management of sustainable energy systems. The company offers an end-to-end software platform that includes modules for modeling and simulation, monitoring and visualization, and controls and management. This comprehensive approach allows customers to optimize distributed generation, energy storage, and other complementary distributed energy resources. By utilizing proprietary technology to simulate the performance of energy assets, Iteros enhances the reliability and sustainability of energy grids. This enables energy businesses to improve resource operations, reduce energy costs, and maximize returns on investment.

ALung

Series C in 2017
ALung Technologies is a medical device manufacturing company based in Pittsburgh, Pennsylvania, founded in 1997. The company specializes in developing devices for gas exchange to treat acute and chronic respiratory disorders. Its primary product, the Hemolung Respiratory Assist System (RAS), functions as a dialysis-like alternative or supplement to mechanical ventilation, allowing physicians to effectively remove carbon dioxide from the blood without relying solely on the lungs. This technology aims to reduce the need for intubation and invasive ventilation, thereby improving patient outcomes. Additionally, ALung offers the Hattler Catheter, which facilitates the insertion of its gas exchange devices into the central venous bloodstream.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.